Compare ZIM & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZIM | PBLS |
|---|---|---|
| Founded | 1945 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.6B |
| IPO Year | 2020 | 2026 |
| Metric | ZIM | PBLS |
|---|---|---|
| Price | $25.01 | $30.76 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $19.26 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 502.7K |
| Earning Date | 05-20-2026 | N/A |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.33 | $25.56 |
| 52 Week High | $29.97 | $33.65 |
| Indicator | ZIM | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 56.52 |
| Support Level | $23.11 | $26.83 |
| Resistance Level | $26.16 | $33.65 |
| Average True Range (ATR) | 0.58 | 2.62 |
| MACD | 0.12 | 0.14 |
| Stochastic Oscillator | 70.26 | 63.76 |
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.